Healthcare Services

Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Rare Disease Diagnostics Market By 2030 Starting From Its 2026 Size?

The rare disease diagnostics market size has experienced robust growth in recent years. It is projected to expand from $38.14 billion in 2025 to $41.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. The historical growth in this market can be attributed to the expansion of genetic testing availability, rising awareness of rare diseases among clinicians, increasing use of molecular diagnostics, growth of specialized diagnostic laboratories, and improved access to advanced imaging technologies.

The rare disease diagnostics market is projected to experience substantial expansion in the coming years, reaching a valuation of $62.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. This anticipated growth over the forecast period is propelled by factors such as the wider adoption of personalized medicine, increased investment in genomics research, a heightened need for early detection of rare diseases, the growing incorporation of AI-powered diagnostic instruments, and the expansion of rare disease screening initiatives. Key trends anticipated during this period encompass the increasing uptake of next-generation sequencing diagnostics, a surge in the application of multi-gene panel testing, the growing integration of advanced imaging technologies for rare disease diagnosis, the establishment of more centralized rare disease testing facilities, and a sharpened emphasis on prompt and precise diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

Which Market Drivers Are Supporting The Expansion Of The Rare Disease Diagnostics Market?

The future expansion of the rare disease diagnostics market is anticipated to be driven by the rising occurrence of rare diseases. These health conditions, which affect a small proportion of the population compared to more common diseases, frequently necessitate specialized diagnostic tools for early and accurate detection. Rare disease diagnostics help improve disease management, enable the identification of potential therapeutics, and reduce unnecessary or harmful treatments, thereby supporting more effective patient care. To illustrate, in March 2025, Kidney Research UK, an UK-based kidney disease charity, stated that the current rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Consequently, the heightened incidence of rare diseases is fueling the growth of the rare disease diagnostics market.

Which Segment Categories Define The Rare Disease Diagnostics Market?

The rare disease diagnostics market covered in this report is segmented –

1) By Test Type: Genetic Test, General Lab Test, Imaging Test

2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

Subsegments:

1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

What Trends Are Projected To Affect The Rare Disease Diagnostics Market?

Major companies operating in the rare disease diagnostics market are prioritizing the creation of advanced solutions, including high-sensitivity whole genome sequencing (WGS) platforms, to elevate diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. These high-sensitivity WGS platforms allow for a comprehensive analysis of nearly all disease-causing genetic variants in a single test, thereby supporting earlier and more accurate diagnoses. For instance, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an improved next-generation sequencing (NGS)-based whole genome sequencing solution tailored for the diagnosis of rare and neurodegenerative diseases. The platform offers broad variant coverage, encompassing Copy Number Variations (CNVs) associated with spinal muscular atrophy (SMA) and intricate pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to mitigate sequencing bias in difficult genomic regions, facilitating higher-quality data and deeper insight into coding, regulatory, and intronic areas to support more precise clinical interpretation.

Who Are The Top Companies Competing In The Rare Disease Diagnostics Market?

Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

Read the full rare disease diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

How Is The Rare Disease Diagnostics Market Distributed Across Key Geographic Regions?

North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Disease Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

Rare Disease Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Rare Diseases Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Rare Inflammatory Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795